Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?
Licht
J D
JD
Derald H. Ruttenberg Cancer Center and Department of Medicine, Mount Sinai School of Medicine, Box 1130, One Gustave L. Levy Place, New York, New York 10029, USA. jonathan.licht@mssm.edu
D002448:Cell Adhesion; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000378:metabolism; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics* / Q000378:metabolism*; D011993:Recombinant Fusion Proteins; D014158:Transcription, Genetic; D014212:Tretinoin / Q000378:metabolism; D000077337:Vorinostat
D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D011993:Recombinant Fusion Proteins; D014212:Tretinoin; D000077337:Vorinostat; D006655:Histone Deacetylases